Acceptance and Adherence of Oral Endocrine Therapy in Women with Metastatic Breast Cancer: Exacampania Group Study
Raffaele Addeo(George Moore Community Clinic), Salvatore Del Prete(Federico II University Hospital), Luigi Maiorino(Medical Center Hospital), Roberto Mabilia(Ospedale Sant'Anna), Agata Pisano(University of Campania "Luigi Vanvitelli"), Antonio Febbraro(Fatebenefratelli Hospital), Pasquale Incoronato, Patrizia Iodice(Ospedale Versilia), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 8
Related Papers
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234
Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide With or Without Bevacizumab as First-Line Treatment in Extensive-Disease Small-Cell Lung Cancer: The GOIRC-AIFA FARM6PMFJM Trial
|Journal of Clinical Oncology|2017|186
Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study
|The Journal of Clinical Endocrinology & Metabolism|2019|180
Randomized Trial Comparing Cisplatin, Gemcitabine, and Vinorelbine With Either Cisplatin and Gemcitabine or Cisplatin and Vinorelbine in Advanced Non–Small-Cell Lung Cancer: Interim Analysis of a Phase III Trial of the Southern Italy Cooperative Oncology Group
|Journal of Clinical Oncology|2000|177
Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors
|The Oncologist|2014|103